NRP1 and breast carcinoma: Together with the known drawbacks of targeting VEGF signaling in metastatic breast cancer, our findings may, in part, serve to explain the clinical inability of NRP1 antibody blockade to effectively inhibit metastatic tumor progression [36, 48].